Compound Annual Growth Rate of 52.9% Over Four Years
Kiwoom Securities Appointed as IPO Underwriter

Enventric, a company specializing in vascular medical devices, has successfully completed a pre-IPO (pre-initial public offering equity investment) round totaling 34.5 billion won. This is interpreted as a result of the high valuation placed on the company's proprietary technology in the cerebral infarction treatment device market.


According to Enventric on June 10, major institutional investors joined as new participants in this round, including Lofty Rock Investment, Moneyball Ventures, Moneyball Partners, Scale Up Partners, Shinhan Venture Investment, Shinhan Capital, IPS Ventures, Aju IB Investment, HB Investment, LB Investment, Quad Asset Management, Pacific Capital, Plexus Partners, and Heungkuk Securities.

Enventric Raises 34.5 Billion Won in Pre-IPO Funding View original image

Among these, Shinhan Capital, IPS Ventures, Quad Asset Management, and Heungkuk Securities, which were existing investors, also participated in this round as follow-on investors. Partnerships with other existing investors such as Devsisters Ventures, Medici Investment, Bluepoint Partners, IBK Capital, Jin & Investment Partners, Forest Partners, Premier Partners, and Korea Development Bank remain strong.


Enventric continues to demonstrate robust financial growth based on its proprietary technology. Over the past four years, the company has achieved cumulative revenue of approximately 6 billion won, with a compound annual growth rate (CAGR) of 52.9% during this period. The newly secured funds will be focused on strengthening research and development (R&D) capabilities, expanding manufacturing infrastructure, and entering global markets.


The company is also accelerating preparations for its listing on the KOSDAQ market. Enventric has already appointed Kiwoom Securities as its IPO underwriter and has entered the IPO phase. In January of this year, following the regulatory approval of its distal access catheter (DAC) "EvoGlide," Enventric also obtained product approval for its stent retriever "ULTRIVA" from the Ministry of Food and Drug Safety, thus building a core lineup of devices for cerebral infarction treatment.



Min Jiyeong and Min Seongwoo, co-CEOs of Enventric, stated, "This investment round confirms the market's confidence in Enventric's technological prowess and growth potential," adding, "We will accelerate our efforts for global market expansion and IPO preparations using the newly raised capital."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing